drugset / Trial / NCT01605084
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the proportion of subjects with HIV-1 RNA \< 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor
Timeline
- Start
- 2012-06-30
- Primary completion
- 2014-08-31
- Completion
- 2014-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 300 mg | Oral |
| Subject | Darunavir | Small molecule | 800 mg | Oral |
| Background | Abacavir | Other / unclassified | 300 mg | — |
| Background | Abacavir | Other / unclassified | 600 mg | — |
| Background | Didanosine | Small molecule | 250 mg | — |
| Background | Didanosine | Small molecule | 400 mg | — |
| Background | Lamivudine | Other / unclassified | 150 mg | — |
| Background | Lamivudine | Other / unclassified | 300 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |
| Background | Stavudine | Other / unclassified | 30 mg | — |
| Background | Stavudine | Other / unclassified | 40 mg | — |
| Background | Tenofovir | Small molecule | 300 mg | — |
| Background | Zidovudine | Small molecule | 300 mg | — |
| Background | emtricitabine | Other / unclassified | 200 mg | — |